January 4, 2025 Top High-Yield Dividend Stocks To Watch For 2025
December 22, 2024 What About Federal Reserve Rates Cut?
December 20, 2024 Honda-Nissan Alliance: A Bold Move To Dominate Auto Industry
December 13, 2024 Trump’s Plan: Potential Shake-Up For Bank Regulators
Tesla: High Hopes, Low Deliveries
Nvidia: Don’t Expect Major Gains From Here (Technical Analysis)
3M Company: Laying The Groundwork For Margin Expansion
Pop Goes The Tesla (Our Top Short For 2025)
Apple: A Piece Of This Pie Is Too Expensive For Me
January 1, 2025 Advanced Charting Tools For Traders
December 21, 2024 Why Is Trading Important?
December 21, 2024 Best AI Trading & Performance Tools
December 21, 2024 Best Economic Calendars For Traders
December 9, 2024 When to Switch Payroll Solutions and How to Make a Smooth Transition
Teladoc Health (TDOC) Stock Forecast for 2024, 2025, 2026. Sell or Buy?
Updated: January 18, 2025 (09:44)
Sector: HealthcareThe share price of Teladoc Health, Inc. (TDOC) now
News Impact Analyzer
Full report|
This Week
|
Bullish | Impact: 5 | News: 1 (1/0/0) |
|
Previous Week
|
Na | Impact: Na | News: Na |
|
Two Weeks Ago
|
Na | Impact: Na | News: Na |
|
Three Weeks Ago
|
Na | Impact: Na | News: Na |
Analysts predictions
Full report|
This Week
|
Neutral | Opinions: Na |
|
Previous Week
|
Neutral | Opinions: Na |
|
Two Weeks Ago
|
Neutral | Opinions: Na |
|
Three Weeks Ago
|
Neutral | Opinions: 1 |
Analyzing the Most Important TDOC news
Teladoc Soars on Strategic Amazon Partnership
Goldman Sachs Sees Bright Future for Teladoc with 56% Upside
Teladoc Health Sees US Revenue Drop as International Growth Shines
Historical and forecast chart of Teladoc Health stock
The chart below shows the historical price of Teladoc Health stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Teladoc Health stock price can be found in the table below.
Long-term forecasts by years.
Teladoc Health, Inc. Analysts predictions review
As of now, Panda has combed through 1 analytical articles which are directly related to TDOC from the last 30 days. Out of these, 0 clearly showcase a bullish trend, while 0 see a bearish trend as the more likely scenario, and 1 stay neutral.
To identify the dominant trend, we took into account analytical articles from the past 30 days, spanning from Dec 20, 2024 to Dec 20, 2024.
Teladoc's Value Appeal Overshadowed by Lingering Growth Doubts
In this review, we delve into an analytical financial article by Deep Value Investing, which maintains a Neutral stance on TDOC stock. The author, with 146 publications since becoming a contributor in 2024, showcases a prolific output indicating a strong commitment to financial analysis and insight. Holding a substantial number of subscribers, 3738 to be precise, showcases the popularity of the author's viewpoints within the investment community. Although the author's authority level suggests a relatively modest credibility compared to industry giants, the dedication to frequent contributions reflects a considerable effort to engage readers and offer valuable perspectives. This review will explore the intricacies of TDOC's financial standing as analyzed by Deep Value Investing, offering an unbiased look at the author's balanced outlook on this stock.
Key Theses of Teladoc Analysis
- Teladoc trades at a significant discount compared to sector peers, making it appealing to value investors.
- The company lacks a compelling growth narrative to drive positive investor sentiment and turnaround.
- Cost-cutting measures alone may not lead to sustainable growth or a shift in sentiment.
- The new AI virtual sitter product may face regulatory challenges and limited demand.
- Investor confidence and clear paths to growth are necessary for a share price rally.
Factors Influencing TDOC Stock Price
Valuation Metrics
Teladoc is trading at just 6x forward operating cash flow, which is 60% below the sector median, potentially attracting value investors. However, this low valuation alone may not shift the negative sentiment without a strong narrative.
Lack of Growth Narrative
The absence of a compelling forward-looking narrative significantly impacts investor confidence and holds back share price recovery. Investors are waiting for evidence of sustainable growth initiatives beyond just cost-cutting.
Cost-Cutting Measures
While cost reductions can improve short-term financials, they may not generate long-term growth or sentiment shifts, particularly as marketing and R&D cuts hamper expansion. They reflect a focus on efficiency over aggressive growth strategies.
AI Virtual Sitter Product
Despite its potential, regulatory and trust hurdles could limit the AI virtual sitter's implementation and demand. Current healthcare solutions may already adequately address patient monitoring needs, reducing potential demand.
Expansion Strategies
International market expansion and BetterHelp’s integration with insurance plans offer growth potential, but are still in early development stages, contributing uncertain future revenue. Success in these areas could meaningfully impact investor sentiment.
Review the original Analysis
Teladoc's Undervaluation: A Golden Opportunity Amid Growth Prospects
In a recent analytical financial article, Michael Wiggins De Oliveira expresses a strong bullish stance on TDOC stock, reflecting his confidence in its potential growth. As a contributor with an impressive 2,828 publications since 2014, Michael has shown significant dedication and expertise in financial analysis. His consistent output, coupled with nearly 50,000 subscribers, underscores his popularity and the trust readers place in his insights. With a credibility rating that places him in the excellent category, Michael’s views carry significant weight in the investment community. This review delves into his compelling arguments supporting TDOC's outlook, providing readers with valuable perspectives from an authoritative voice in financial analysis.
Key Theses of the Analysis
- Teladoc Health, Inc. (TDOC) is currently undervalued and presents a compelling investment opportunity due to its low trading multiple of 11x forward free cash flow.
- The company's strengths include scalable virtual healthcare services, focusing on chronic condition management and international expansion.
- Stabilizing revenue growth rates around 1% in 2025 is essential for Teladoc's future valuation and prospects.
- The arrival of a new management team could inject fresh energy and facilitate transformational changes.
- A price target of $15 per share is projected by early 2026, assuming modest growth and cost optimizations.
Factors Influencing Teladoc's Stock Price
Undervaluation Based on Free Cash Flow
Teladoc's stock is considered undervalued, trading at 11x forward free cash flow. This undervaluation creates a significant upside potential if the company stabilizes and begins to grow its revenues.
Potential Revenue Growth Stabilization
Achieving a projected stabilization of revenue growth rates around 1% by 2025 is crucial; failure to stabilize could hurt investor confidence and suppress stock prices. However, successful stabilization would support the bullish thesis.
New Management Team
The arrival of a new management team may drive transformational changes, potentially positive for the company’s future prospects and investor sentiment. While too early to determine definitive outcomes, the potential for positive changes could lift the narrative around the stock.
Challenges in the Telehealth Market
Intensified competition and rising healthcare costs pressure Teladoc, especially in chronic care management, which may impact profitability if not managed. This is considered already priced in, but any worsening could further suppress stock prices.
International Expansion and Chronic Condition Management
Successfully expanding its international presence and chronic condition management offerings could enhance growth prospects and counterbalance other market pressures. This strategy could improve investor perception and valuation over time.
Review the original Analysis
Commentary
Teladoc Health presents an enticing investment opportunity due to its significant undervaluation, trading at only 11 times forward free cash flow. There's promising potential for growth if Teladoc can stabilize its revenue pace, projecting a modest 1% by 2025—a pivotal factor in improving the company's valuation. The entry of a new leadership team could be a game-changer, potentially sparking transformative initiatives that align with its expanding international footprint and chronic condition management ambitions. All these aspects potentially amplify Teladoc's value proposition, positioning it as a favorable option for investors looking to capitalize on its underappreciated prospects.
Assessing the average impact strength of factors, the potential stabilization of revenue growth and the push for international expansion significantly contribute positively to its stock trends. With a combined average significance of 6.4 out of 10, these elements suggest there's a steady bullish trend emerging, possibly lasting over the next month. The narrative lacks the rigidity of traditional commentary, providing a grounded perspective for those intrigued by the evolving dynamics of the telehealth sector and Teladoc’s potential revival.
Comprehensive Analysis of Teladoc Health (TDOC) Stock Market Performance
Our multifaceted analysis of Teladoc Health's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Teladoc Health stock?
- When should I record a loss on Teladoc Health stock?
- What are analysts' forecasts for Teladoc Health stock?
- What is the future of Teladoc Health stock?
We forecast Teladoc Health stock performance using neural networks based on historical data on Teladoc Health stocks.
Teladoc Health (TDOC) is a telemedicine software developer that connects patients with doctors through its platform for consulting and monitoring health indicators. With the help of video conferencing of the mobile application, remote medical care is provided to patients with cancer, heart failure and various chronic diseases. The company operates in 130 countries and has already served over 27 million people worldwide.
The company was founded in 2002. Capitalization – $ 22 billion.
Teladoc Health, Inc. News influencing stock rates
As of now, Panda has combed through 1 news items directly related to TDOC from the last 30 days. Out of these, 1 clearly showcase a bullish trend, while 0 display bearish tendencies, and 0 events are neutral.
Based on an analysis of the most important news from the last 30 days affecting TDOC shares, it's clear that bullish sentiments are completely overshadowing bearish ones. The impact of positive news is more than five times as dominant as that of negative developments.
The news analyzed fell within the period from Jan 14, 2025, to Jan 14, 2025.
Teladoc Surges 7% After Beating Q3 Expectations
Teladoc Surpasses Earnings Expectations with Strong Q3 Performance
Teladoc Health Awaits Critical Q3 Updates Amid BetterHelp Struggles
DEA Extends Lifeline for Telehealth Firms: Prescribing Flexibilities to Continue
Teladoc Health Faces Structural Shift as COO Resigns
Teladoc Surges 7% as Jefferies Sees Short-Term Upside After BetterHelp Turnaround
Intel's Restructuring Surge and AppLovin's Upgrade Lift Markets
Teladoc Health Stock Breaks Losing Streak with Modest Gain
Tech Tsunami: META Soars While TDOC Sinks
Teladoc Plummets 16% After Scrapping 2024 Guidance and Long-Term Outlook
Teladoc Health daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan 20 | 9.03 | 8.89 | 9.12 | 2.58 |
| Jan 21 | 9.06 | 8.93 | 9.13 | 2.19 |
| Jan 22 | 9.09 | 8.95 | 9.15 | 2.27 |
| Jan 23 | 8.93 | 8.89 | 9.01 | 1.35 |
| Jan 24 | 8.89 | 8.85 | 8.95 | 1.13 |
| Jan 25 | 9.06 | 9.00 | 9.14 | 1.51 |
| Jan 26 | 9.02 | 8.94 | 9.09 | 1.63 |
| Jan 27 | 9.02 | 8.88 | 9.13 | 2.84 |
| Jan 28 | 9.19 | 9.13 | 9.31 | 1.99 |
| Jan 29 | 9.28 | 9.15 | 9.41 | 2.92 |
| Jan 30 | 9.23 | 9.15 | 9.34 | 2.08 |
| Jan 31 | 9.14 | 9.10 | 9.28 | 1.95 |
| Feb 01 | 9.21 | 9.18 | 9.28 | 1.10 |
| Feb 02 | 9.18 | 9.12 | 9.26 | 1.53 |
| Feb 03 | 9.10 | 8.95 | 9.16 | 2.26 |
| Feb 04 | 9.20 | 9.16 | 9.26 | 1.19 |
| Feb 05 | 9.28 | 9.14 | 9.37 | 2.54 |
| Feb 06 | 9.28 | 9.15 | 9.37 | 2.46 |
| Feb 07 | 9.20 | 9.16 | 9.29 | 1.39 |
| Feb 08 | 9.25 | 9.16 | 9.37 | 2.30 |
| Feb 09 | 9.31 | 9.23 | 9.45 | 2.36 |
| Feb 10 | 9.14 | 9.06 | 9.19 | 1.43 |
| Feb 11 | 9.27 | 9.18 | 9.40 | 2.34 |
| Feb 12 | 9.28 | 9.14 | 9.38 | 2.64 |
| Feb 13 | 9.33 | 9.19 | 9.44 | 2.64 |
| Feb 14 | 9.45 | 9.41 | 9.49 | 0.90 |
| Feb 15 | 9.36 | 9.23 | 9.40 | 1.87 |
| Feb 16 | 9.41 | 9.34 | 9.55 | 2.16 |
| Feb 17 | 9.41 | 9.37 | 9.53 | 1.71 |
| Feb 18 | 9.50 | 9.39 | 9.63 | 2.57 |
Teladoc Health Daily Price Targets
Teladoc Health Stock Forecast 01-20-2025.
Forecast target price for 01-20-2025: $9.03.
Negative dynamics for Teladoc Health shares will prevail with possible volatility of 2.516%.
Pessimistic target level: 8.89
Optimistic target level: 9.12
Teladoc Health Stock Forecast 01-21-2025.
Forecast target price for 01-21-2025: $9.06.
Positive dynamics for Teladoc Health shares will prevail with possible volatility of 2.144%.
Pessimistic target level: 8.93
Optimistic target level: 9.13
Teladoc Health Stock Forecast 01-22-2025.
Forecast target price for 01-22-2025: $9.09.
Positive dynamics for Teladoc Health shares will prevail with possible volatility of 2.224%.
Pessimistic target level: 8.95
Optimistic target level: 9.15
Teladoc Health Stock Forecast 01-23-2025.
Forecast target price for 01-23-2025: $8.93.
Negative dynamics for Teladoc Health shares will prevail with possible volatility of 1.328%.
Pessimistic target level: 8.89
Optimistic target level: 9.01
Teladoc Health Stock Forecast 01-24-2025.
Forecast target price for 01-24-2025: $8.89.
Negative dynamics for Teladoc Health shares will prevail with possible volatility of 1.113%.
Pessimistic target level: 8.85
Optimistic target level: 8.95
Teladoc Health Stock Forecast 01-25-2025.
Forecast target price for 01-25-2025: $9.06.
Positive dynamics for Teladoc Health shares will prevail with possible volatility of 1.487%.
Pessimistic target level: 9.00
Optimistic target level: 9.14
TDOC (TDOC) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Feb. | 9.18 | 8.68 | 9.94 | 12.70 |
| Mar. | 9.35 | 8.71 | 10.07 | 13.48 |
| Apr. | 8.83 | 8.10 | 9.34 | 13.21 |
| May. | 8.21 | 7.77 | 8.62 | 9.85 |
| Jun. | 7.48 | 7.09 | 8.03 | 11.68 |
| Jul. | 7.41 | 7.07 | 7.63 | 7.26 |
| Aug. | 7.70 | 7.50 | 8.29 | 9.50 |
| Sep. | 7.41 | 6.77 | 7.89 | 14.25 |
| Oct. | 7.22 | 6.72 | 7.71 | 12.78 |
| Nov. | 7.37 | 6.82 | 8.01 | 14.78 |
| Dec. | 7.54 | 7.15 | 8.07 | 11.30 |
Teladoc Health forecast for this year
Teladoc Health Stock Prediction for Feb 2025
An uptrend is forecast for this month with an optimal target price of $9.18497. Pessimistic: $8.68. Optimistic: $9.94
Teladoc Health Stock Prediction for Mar 2025
An uptrend is forecast for this month with an optimal target price of $9.34662. Pessimistic: $8.71. Optimistic: $10.07
Teladoc Health Stock Prediction for Apr 2025
An downtrend is forecast for this month with an optimal target price of $8.83256. Pessimistic: $8.10. Optimistic: $9.34
Teladoc Health Stock Prediction for May 2025
An downtrend is forecast for this month with an optimal target price of $8.21075. Pessimistic: $7.77. Optimistic: $8.62
Teladoc Health Stock Prediction for Jun 2025
An downtrend is forecast for this month with an optimal target price of $7.47917. Pessimistic: $7.09. Optimistic: $8.03
Teladoc Health Stock Prediction for Jul 2025
An downtrend is forecast for this month with an optimal target price of $7.40513. Pessimistic: $7.07. Optimistic: $7.63
Teladoc Health Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $7.69837. Pessimistic: $7.50. Optimistic: $8.29
Teladoc Health Stock Prediction for Sep 2025
An downtrend is forecast for this month with an optimal target price of $7.41045. Pessimistic: $6.77. Optimistic: $7.89
Teladoc Health Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $7.22297. Pessimistic: $6.72. Optimistic: $7.71
Teladoc Health Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $7.36598. Pessimistic: $6.82. Optimistic: $8.01
Teladoc Health Stock Prediction for Dec 2025
An uptrend is forecast for this month with an optimal target price of $7.53613. Pessimistic: $7.15. Optimistic: $8.07
Teladoc Health (TDOC) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 6.92 | 6.63 | 7.21 | 8.02 |
| Feb | 6.85 | 6.42 | 7.31 | 12.16 |
| Mar | 7.10 | 6.63 | 7.49 | 11.47 |
| Apr | 7.14 | 6.74 | 7.41 | 9.01 |
| May | 6.80 | 6.32 | 7.02 | 10.02 |
| Jun | 6.76 | 6.49 | 7.29 | 10.92 |
| Jul | 6.99 | 6.47 | 7.45 | 13.21 |
| Aug | 6.82 | 6.63 | 7.23 | 8.30 |
| Sep | 7.03 | 6.50 | 7.60 | 14.55 |
| Oct | 7.30 | 6.76 | 7.92 | 14.60 |
| Nov | 7.33 | 6.78 | 7.84 | 13.48 |
| Dec | 6.76 | 6.26 | 7.07 | 11.37 |
Teladoc Health (TDOC) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 6.56 | 6.41 | 7.12 | 10.03 |
| Feb | 6.31 | 6.16 | 6.54 | 5.84 |
| Mar | 6.57 | 6.15 | 6.72 | 8.49 |
| Apr | 6.94 | 6.69 | 7.16 | 6.61 |
| May | 6.51 | 6.20 | 6.74 | 8.07 |
| Jun | 6.29 | 5.77 | 6.44 | 10.32 |
| Jul | 6.36 | 6.12 | 6.92 | 11.53 |
| Aug | 5.92 | 5.61 | 6.33 | 11.42 |
| Sep | 5.66 | 5.51 | 6.03 | 8.67 |
| Oct | 6.28 | 6.07 | 6.70 | 9.29 |
| Nov | 6.92 | 6.64 | 7.41 | 10.47 |
| Dec | 7.23 | 6.93 | 7.51 | 7.72 |
Teladoc Health information and performance
2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE, NY, US
Market capitalization of the Teladoc Health, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of TDOC shares in the company outstanding by the market price of one share.
EBITDA of Teladoc Health is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Commentary
Teladoc Health (TDOC) presents an intriguing investment opportunity due to its attractive valuation, currently trading at a significant discount compared to its sector peers. However, while the stock's low valuation is a beacon for value investors, the lack of a compelling growth narrative muddles the waters. With an average influence score of around seven, factors like valuation and expansion strategies provide some support for a potential stock uptick, but investor sentiment remains tethered to the company's ability to demonstrate sustainable growth paths.
In the short term, cost-cutting measures and the AI virtual sitter product offer limited impact on TDOC's stock trend, as rigid market responses and regulatory challenges loom large. Expansion efforts and BetterHelp’s insurance integrations are promising yet vague, with actual returns on these initiatives still in the wings. As it stands, these factors shape a neutral outlook for Teladoc's stock trend over the next month, leaving much to be desired in terms of a convincing narrative that could truly lift investor spirits.